Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,236 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
Kawakami M, Kawakami K, Puri RK. Kawakami M, et al. Among authors: kawakami k. J Neurooncol. 2003 Oct;65(1):15-25. doi: 10.1023/a:1026294416718. J Neurooncol. 2003. PMID: 14649882 Review.
Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R.
Kioi M, Kawakami K, Puri RK. Kioi M, et al. Among authors: kawakami k. Cell Immunol. 2004 May;229(1):41-51. doi: 10.1016/j.cellimm.2004.06.005. Cell Immunol. 2004. PMID: 15331327
Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M, Kawakami K, Puri RK. Kioi M, et al. Among authors: kawakami k. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6231-8. doi: 10.1158/1078-0432.CCR-04-0700. Clin Cancer Res. 2004. PMID: 15448012
In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds to IL-13 receptor with a higher affinity compared with wild-type IL-13. …
In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted …
TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.
Honjo Y, Bian Y, Kawakami K, Molinolo A, Longenecker G, Boppana R, Larsson J, Karlsson S, Gutkind JS, Puri RK, Kulkarni AB. Honjo Y, et al. Among authors: kawakami k. Cell Cycle. 2007 Jun 1;6(11):1360-6. doi: 10.4161/cc.6.11.4268. Epub 2007 Jun 5. Cell Cycle. 2007. PMID: 17534148
Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK. Kawakami K, et al. Clin Cancer Res. 2006 Aug 1;12(15):4678-86. doi: 10.1158/1078-0432.CCR-06-0192. Clin Cancer Res. 2006. PMID: 16899618
Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK. Kawakami K, et al. Among authors: kawakami m. Cancer Res. 2006 Apr 15;66(8):4434-42. doi: 10.1158/0008-5472.CAN-05-1265. Cancer Res. 2006. PMID: 16618770
Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Kioi M, et al. Among authors: kawakami m, kawakami k. Cancer Res. 2005 Sep 15;65(18):8388-96. doi: 10.1158/0008-5472.CAN-05-1043. Cancer Res. 2005. PMID: 16166317
Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K, Kawakami M, Liu Q, Puri RK. Kawakami K, et al. Among authors: kawakami m. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):230-7. doi: 10.1016/j.ijrobp.2005.05.017. Int J Radiat Oncol Biol Phys. 2005. PMID: 16111594
Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
Kawakami K. Kawakami K. Curr Gene Ther. 2005 Apr;5(2):213-23. doi: 10.2174/1566523053544227. Curr Gene Ther. 2005. PMID: 15853729 Review.
Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK. Kawakami K, et al. Among authors: kawakami m. J Immunother. 2005 May-Jun;28(3):193-202. doi: 10.1097/01.cji.0000161393.04207.e1. J Immunother. 2005. PMID: 15838375
2,236 results
Jump to page
Feedback